CARE Trial

Jump to navigation Jump to search

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

CARE Trial On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of CARE Trial

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on CARE Trial

CDC on CARE Trial

CARE Trial in the news

Blogs on CARE Trial

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for CARE Trial

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Click here to download slides for CARE Trial.

Objective

To assess if pravastatin would reduce the sum of fatal coronary artery disease (CAD) and nonfatal myocardial infarction (MI) in patients who had a previous MI and a total cholesterol value < 240 mg/dl.

Methods

Cholesterol and Recurrent Events trial was a double blinded, randomized study wherein 4159 patients with a history of a myocardial infarction in the previous two years who had a total cholesterol value < 240 mg/dl were enrolled and treated with either 40 mg pravastatin or a placebo.

Results

The following results were obtained after a median follow-up time of 5 years:

  • Reduced combined end point of coronary death and nonfatal MI (10.2 versus 13.2 percent)
  • Reduced need for revascularization with CABG or PTCA (14.1 versus 18.8 percent)
  • Reduced frequency of stroke (2.6 versus 3.8 percent) and of stroke plus transient ischemic attacks (4.4 versus 6.0 percent)[1][2]

References

  1. Sacks FM, Pfeffer MA, Moye LA; et al. (1996). "The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators". The New England Journal of Medicine. 335 (14): 1001–9. doi:10.1056/NEJM199610033351401. PMID 8801446. Unknown parameter |month= ignored (help)
  2. Pfeffer MA, Sacks FM, Moyé LA; et al. (1995). "Cholesterol and Recurrent Events: a secondary prevention trial for normolipidemic patients. CARE Investigators". The American Journal of Cardiology. 76 (9): 98C–106C. PMID 7572695. Unknown parameter |month= ignored (help)